BioRestorative Therapies (BRTX) Common Equity (2010 - 2025)

BioRestorative Therapies (BRTX) has reported Common Equity for 16 consecutive years, with $356744.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 95.82% year-over-year to $356744.0; the trailing twelve-month figure through Dec 2025 stood at $356744.0 (down 95.82% YoY), and the FY2025 full-year result was $356744.0, down 95.82% from the prior year.
• Common Equity declined to $356744.0 in Q4 2025 per BRTX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Common Equity topped out at $14.5 million in Q1 2024 and bottomed at -$4.9 million in Q3 2021.
• Historically, Common Equity has averaged $6.2 million across 5 years, with a median of $7.5 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Common Equity jumped 909.82% in 2021, then plunged 95.82% in 2025.
• Over 5 years, Common Equity stood at $10.8 million in 2021, then dropped by 4.57% to $10.3 million in 2022, then declined by 2.78% to $10.0 million in 2023, then fell by 14.72% to $8.5 million in 2024, then slumped by 95.82% to $356744.0 in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $356744.0, $2.2 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.